Benzinga - by Vandana Singh, Benzinga Editor.
Since Monday, Eli Lilly And Co (NYSE:LLY) shares have gained 8%, closing at $724.85 on Wednesday, sending the market capitalization to a whopping $690 billion (roughly).
Thursday, shares are trading with a session volume of 25.301K compared to an average volume of 3.277 million, as per data from Benzinga Pro.
Tuesday, the company released much-awaited, better-than-expected fourth-quarter results. Eli Lilly expects fiscal year 2024 sales of $40.4 billion-$41.6 billion versus the consensus of $39.14 billion and fiscal year 2023 sales of $34.12 billion.
During CNBC’s ‘Halftime Report,’ the committee noted that “in the instance of Eli Lilly, there is more to go in the stock.”
- BMO Capital raised the price target from $710 to $865.
- BofA Securities raised the price target to $800, up from $750.
- Wells Fargo maintained an Overweight and raised the price target from $700 to $825.
- Barclays reiterated an Overweight rating and raised the price target from $680 to $810.
- Morgan Stanley maintained the Overweight rating with a price target up from $763 to $805.
- Truist Securities maintained the Buy rating and raised the price target from $650 to $850.
As part of the settlement, Reuters noted that Eli Lilly will provide low-cost insulin to patients and donate free insulin to 15 clinics in Minnesota.
In Minnesota, paying out-of-pocket patients can access Eli Lilly’s insulin products for a maximum of $35 per month. Even those with insurance can opt to pay $35 instead of using their coverage.
The settlement, effective for five years, aims to address the affordability of life-sustaining insulin.
The lawsuit, initiated by Minnesota in 2018, is still pending against Novo Nordisk A/S (NYSE:NVO) and Sanofi SA (NASDAQ:SNY).
In March of the previous year, Eli Lilly had already committed to reducing insulin prices, offering it to many patients at $25 or $35.
Price Action: LLY shares are up 1.91% at $739.15 on the last check Thursday.
Photo by rafapress on Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.